Authors: Jarmila Vinšová and Martin Krátký (Charles University, the Czech Republic)
Book Description: The emergence of resistance to anti-tuberculosis drugs, particularly of MDR-TB and newly XDR-TB, has become a major public health problem. The current treatment regiment has several disadvantages, i.e. long treatment period (DOTS takes minimum 6 months) during which tubercle bacilli mutant become resistant to one or more drugs; side effects of the used drugs; co-infection of HIV/AIDS. The emergence of MDR-TB has made many currently available anti-TB drugs ineffective. Sleeping latent forms of mutant bacilli resistant against common anti-TB drugs pose the risk of epidemic for the new generation. This book outlines the recent advances in the development of new multi-drug-resistant tuberculosis (MDR-TB) drugs.
We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.
Table of Contents: 1. Introduction
2. Resistance to Commonly Used Drugs, Mechanism of the Action, pp. 1-7
3. Research of Novel MDR Potential Drugs, pp. 9-68
4. Conclusion, pp. 69
Series: Pharmacology - Research, Safety Testing and Regulation